Phenotype and function of NK cell in colorectal cancer

doi:10.3969/j.issn.1674-8115.2024.06.006

Abstract

Abstract:

Objective ·To investigate the composition of immune cells in tumor microenvironment of colorectal cancer (CRC), and examine the proportion, phenotype and effector function of natural killer (NK) cells in CRC. Methods ·Fresh tumor tissues, paired normal tissues adjacent to tumor, and peripheral blood samples in the same cohort were collected from CRC patients. Tissues were digested and prepared into single cell suspension. The major immune cell lineages were detected by flow cytometry. t-Distributed stochastic neighbor embedding (t-SNE) and statistical analysis were used to analyze the composition of immune cells in tumor microenvironment of CRC. To analyze the phenotype of NK cells, the expression levels of activation markers, including CD16, CD27, CD69, human leukocyte antigen-DR (HLA-DR), and T cell immunoglobulin domain and mucin domain-3 (TIM-3), were detected by flow cytometry. NK cell subsets: CD38^lowNK cells and CD38^highNK cells were also examined by flow cytometry. To assess the effector function of NK cells, they were stimulated with cell stimulation cocktail and the expression levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured by flow cytometry. Results ·Twenty-five pairs of fresh tumor tissues and normal tissues adjacent to tumor, and 15 peripheral blood samples in the same cohort were collected from CRC patients. The tumor microenvironment of CRC included diverse immune cell types, including T cells, B cells, NK cells and myeloid cells. The proportions of T cells (P=0.000) and myeloid cells (P=0.026) in tumor tissues were significantly higher than those in normal tissues. By contrast, the proportion of NK cells (P=0.007) in tumor was significantly reduced. The proportion of B cells was comparable between tumor and normal tissues. Compared to normal tissues, NK cells in tumor tissues expressed significantly lower CD27 (P=0.000) and CD69 (P=0.001), while the expression levels of CD16 (P=0.008), HLA-DR (P=0.000) and TIM-3 (P=0.024) were significantly elevated. The results indicated that NK cells in CRC tumor exhibited a phenotype of late activation and exhaustion. According to the expression level of CD38, NK cells could be divided into two subsets, CD38^highNK cells and CD38^lowNK cells. The proportion of CD38^highNK cells (P=0.003) in tumor tissues was significantly lower than that in normal tissues, while the proportion of CD38^lowNK cells was unaffected. Compared to CD38^lowNK cells, CD38^highNK cells expressed higher CD27, meanwhile significantly less CD16, NKp46, CD57, CD94, HLA-DR and CD158a (P=0.000). These results suggested that CD38^highNK cells were at early differentiation state. The secretion of cytokines IFN-γ (P=0.032), TNF-α (P=0.042), and GM-CSF (P=0.019) by tumor-infiltrated NK cells was significantly decreased compared to that in normal tissues. The results showed that the function of tumor-infiltrated NK cells was impaired. Conclusion ·Together, these data suggest that NK cell compartment is disrupted in tumor tissues of CRC, leading to the impaired anti-tumor immunity mediated by NK cells.

Key words: natural killer cell (NK cell), colorectal cancer (CRC), CD38

CLC Number:

R392.12

FENG Xujiao, LIU Jianyue, QI Yangyang, SUN Jing, SHEN Lei. Phenotype and function of NK cell in colorectal cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 713-722.

Figures/Tables 6

TrendMD

References 32

1	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3):233-254.
3	XU L Y, ZHAO J H, LI Z H, et al. National and subnational incidence, mortality and associated factors of colorectal cancer in China: a systematic analysis and modelling study[J]. J Glob Health, 2023, 13: 04096.
4	LI N, LU B, LUO C Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America[J]. Cancer Lett, 2021, 522: 255-268.
5	HOSSAIN M S, KARUNIAWATI H, JAIROUN A A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies[J]. Cancers, 2022, 14(7): 1732.
6	ZENG H M, RAN X H, AN L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): e877-e887.
7	TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J]. Med Sci, 2018, 6(2): 31.
8	MEZHEYEUSKI A, MICKE P, MARTÍN-BERNABÉ A, et al. The immune landscape of colorectal cancer[J]. Cancers (Basel), 2021, 13(21): 5545.
9	LIU S Z, GALAT V, GALAT Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development[J]. J Hematol Oncol, 2021, 14(1): 7.
10	MYERS J A, MILLER J S. Exploring the NK cell platform for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2021, 18(2): 85-100.
11	BRUNI D, ANGELL H K, GALON J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680.
12	TANG Y P, XIE M Z, LI K Z, et al. Prognostic value of peripheral blood natural killer cells in colorectal cancer[J]. BMC Gastroenterol, 2020, 20(1): 31.
13	MENON A G, JANSSEN-VAN RHIJN C M, MORREAU H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis[J]. Lab Invest, 2004, 84(4): 493-501.
14	DONADON M, HUDSPETH K, CIMINO M, et al. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival[J]. J Gastrointest Surg, 2017, 21(8): 1226-1236.
15	HALAMA N, BRAUN M, KAHLERT C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines[J]. Clin Cancer Res, 2011, 17(4): 678-689.
16	COPPOLA A, ARRIGA R, LAURO D, et al. NK cell inflammation in the clinical outcome of colorectal carcinoma[J]. Front Med (Lausanne), 2015, 2: 33.
17	SORRENTINO C, D'ANTONIO L, FIENI C, et al. Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival[J]. Front Immunol, 2021, 12: 778329.
18	JOBIN G, RODRIGUEZ-SUAREZ R, BETITO K. Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy[J]. Gastroenterology, 2017, 153(4): 980-987.
19	GANESH K, STADLER Z K, CERCEK A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
20	BAI Z Y, ZHOU Y, YE Z F, et al. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy[J]. Front Immunol, 2021, 12: 808964.
21	DE VISSER K E, JOYCE J A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403.
22	MASKALENKO N A, ZHIGAREV D, CAMPBELL K S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders[J]. Nat Rev Drug Discov, 2022, 21(8): 559-577.
23	CRINIER A, NARNI-MANCINELLI E, UGOLINI S, et al. SnapShot: natural killer cells[J]. Cell, 2020, 180(6): 1280-1280.e1.
24	HASHEMI E, MALARKANNAN S. Tissue-resident NK cells: development, maturation, and clinical relevance[J]. Cancers, 2020, 12(6): 1553.
25	DOGRA P, RANCAN C, MA W J, et al. Tissue determinants of human NK cell development, function, and residence[J]. Cell, 2020, 180(4): 749-763.e13.
26	CAPUANO C, PIGHI C, BATTELLA S, et al. Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs[J]. Cancers, 2021, 13(10): 2500.
27	MEI Y, XIAO W W, HU H, et al. Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer[J]. Clin Transl Med, 2021, 11(6): e422.
28	MERINO A M, KIM H, MILLER J S, et al. Unraveling exhaustion in adaptive and conventional NK cells[J]. J Leukoc Biol, 2020, 108(4): 1361-1368.
29	GAO L, DU X H, LI J B, et al. Evolving roles of CD38 metabolism in solid tumour microenvironment[J]. Br J Cancer, 2023, 128(4): 492-504.
30	GARS M L, SEILER C, KAY A W, et al. CD38 contributes to human natural killer cell responses through a role in immune synapse formation[Z/OL]. bioRxiv, 2018[2023-11-16]. https://www.biorxiv.org/content/10.1101/349084v2#:~:text=CD38%20localizes%20and%20accumulates%20at%20the%20immune%20synapse,critical%20 role%20in%20NK%20cell%20immune%20synapse%20formation.
31	WEISER M R. AJCC 8th edition: colorectal cancer[J]. Ann Surg Oncol, 2018, 25(6): 1454-1455.
32	DWIVEDI S, RENDÓN-HUERTA E P, ORTIZ-NAVARRETE V, et al. CD38 and regulation of the immune response cells in cancer[J]. J Oncol, 2021, 2021: 6630295.

Reagent name	System
Tumor wash buffer
PBS (1×)	Up to 20 mL (for 1 g biopsies)
DTT (2 mol·L^-1)	65 μL (final 6.5 mmol·mL^-1)
FBS	2 mL (10%)
Normal wash buffer
PBS (1×)	Up to 20 mL (for 1 g biopsies)
HEPES (1 mol·L^-1)	300 μL (final 15 mmol·mL^-1)
EDTA (0.5 mol·L^-1)	200 μL (final 5 mmol·mL^-1)
DTT (2 mol·L^-1)	10 μL (final 1 mmol·mL^-1)
FBS	2 mL (10%)
Tissue digestion buffer
RPMI1640 (+10%FBS, +1%P/S)	Up to 40 mL (for 2 g biopsies)
Col Ⅷ	45.7 μL (final 0.38 mg·mL^-1)
DNase Ⅰ	26.8 μL (final 0.1 mg·mL^-1)

Reagent name	System
Tumor wash buffer
PBS (1×)	Up to 20 mL (for 1 g biopsies)
DTT (2 mol·L^-1)	65 μL (final 6.5 mmol·mL^-1)
FBS	2 mL (10%)
Normal wash buffer
PBS (1×)	Up to 20 mL (for 1 g biopsies)
HEPES (1 mol·L^-1)	300 μL (final 15 mmol·mL^-1)
EDTA (0.5 mol·L^-1)	200 μL (final 5 mmol·mL^-1)
DTT (2 mol·L^-1)	10 μL (final 1 mmol·mL^-1)
FBS	2 mL (10%)
Tissue digestion buffer
RPMI1640 (+10%FBS, +1%P/S)	Up to 40 mL (for 2 g biopsies)
Col Ⅷ	45.7 μL (final 0.38 mg·mL^-1)
DNase Ⅰ	26.8 μL (final 0.1 mg·mL^-1)

Characteristic	Colorectal cancer patient (n=25)
Age/year	62.4±11.8
Gender/n(%)
Male	9 (36.0)
Female	16 (64.0)
Pathological T stage/n(%)
T2	3 (12.0)
T3	18 (72.0)
T4	4 (16.0)
Pathological N stage/n(%)
N0	14 (56.0)
N1	6 (24.0)
N2	5 (20.0)
Pathological M stage/n(%)
M0	24 (96.0)
M1	1 (4.0)
TNM stage/n(%)
Ⅰ	2 (8.0)
Ⅱ	12 (48.0)
Ⅲ	10 (40.0)
Ⅳ	1 (4.0)

Characteristic	Colorectal cancer patient (n=25)
Age/year	62.4±11.8
Gender/n(%)
Male	9 (36.0)
Female	16 (64.0)
Pathological T stage/n(%)
T2	3 (12.0)
T3	18 (72.0)
T4	4 (16.0)
Pathological N stage/n(%)
N0	14 (56.0)
N1	6 (24.0)
N2	5 (20.0)
Pathological M stage/n(%)
M0	24 (96.0)
M1	1 (4.0)
TNM stage/n(%)
Ⅰ	2 (8.0)
Ⅱ	12 (48.0)
Ⅲ	10 (40.0)
Ⅳ	1 (4.0)

[1]	ZHANG Yesheng, YANG Yijing, HUANG Yiwen, SHI Longyu, WANG Manyuan, CHEN Sisi. Research progress in immune cells regulating drug resistance of tumor cells in tumor microenvironment [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 830-838.
[2]	LUO Chen, SHEN Ling, WANG Chuanwei, GU Jiani, WANG Jin, ZHAO Li, HUANG Shuai. Current status and influencing factors of early mobilization of patients undergoing laparoscopic radical resection of colorectal cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1201-1210.
[3]	PENG Tian, XU Leiming. Crosstalk between epigenetic modification and circRNA in colorectal cancer: recent advances [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 237-243.
[4]	HU Muni, JI Linhua, ZHANG Xinyu, SHEN Chaoqin, HONG Jie, CHEN Haoyan. Association analysis of T cell receptor repertoire diversity with clinical characteristics and Fusobacterium nucleatum abundance in colorectal cancer patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1045-1052.
[5]	Ying XU, Yi-min CHU, Da-ming YANG, Ji LI, Hai-qin ZHANG, Hai-xia PENG. Construction of a metastasis prediction model of microsatellite instability-high colorectal cancer based on differentially expressed gene assembly [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1197-1206.
[6]	Ru-juan BAO, Hui-fang CHEN, Yu DONG, You-qiong YE, Bing SU. Construction of prognostic risk score model of colorectal cancer gene signature based on transcriptome dysregulation [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 285-296.
[7]	Wen-hui XU, Jing BIAN, Lei-zhen ZHENG. Research progress of the relationship between high-fat diet and colorectal cancer and its prevention and treatment countermeasures [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(11): 1514-1517.
[8]	YAN Yu-qing, SHEN Chao-qin, CHEN Hao-yan, HONG Jie#, WANG Zhen-hua#. Expression of lnc-MTBP-5 in colorectal cancer and its effect on cell invasion [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1193-1201.